Company Of The Day: Merck
What?
Merck (NYSE:MRK) is preparing a new formulation for its blockbuster cancer immunotherapy Keytruda, which could be injected under the skin.
Why?
- Higher Keytruda Sales To Drive Merck’s Q1?
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- At $100 Does Merck Stock Have Room For Growth?
- Should You Pick Merck Stock Over Coca-Cola?
- Should You Buy Merck Stock After An Upbeat Q2?
- How Has Merck Stock Performed During The 2022-23 Inflation Shock?
Keytruda will see patents start to expire in 2028. Merck believes that the new formulation has the potential to be novel, non-obvious, and useful, implying that it could receive a new patent.
So What?
Keytruda is Merck’s most important drug, generating over $17 billion in sales in 2021. These developments could potentially help the company hold off on a sales decline.
See Our Complete Analysis For Merck
Returns | Dec 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
MRK Return | 0% | 44% | 87% |
S&P 500 Return | 0% | -15% | 82% |
Trefis Multi-Strategy Portfolio | 1% | -17% | 230% |
[1] Month-to-date and year-to-date as of 12/5/2022
[2] Cumulative total returns since the end of 2016